Fujimura, T., Sato, Y., Tanita, K., Kambayashi, Y., Otsuka, A., Fujisawa, Y., . . . Aiba, S. (2018). Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: A pilot study. Oncotarget.
Citación estilo ChicagoFujimura, Taku, et al. "Serum Levels of Soluble CD163 and CXCL5 May Be Predictive Markers for Immune-related Adverse Events in Patients With Advanced Melanoma Treated With Nivolumab: A Pilot Study." Oncotarget 2018.
Cita MLAFujimura, Taku, et al. "Serum Levels of Soluble CD163 and CXCL5 May Be Predictive Markers for Immune-related Adverse Events in Patients With Advanced Melanoma Treated With Nivolumab: A Pilot Study." Oncotarget 2018.